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Background: In patients with diabetes, studies investigating the association between nonalcoholic fatty liver
disease (NAFLD) and coronary artery calcium score (CACS) have shown conflicting results. The aim of this study was
to evaluate the association between NAFLD and CACS in diabetic patients.
Methods: This is the cohort study performed in Seoul National University Hospital Gangnam Healthcare Center.
NAFLD was defined as cases with the typical ultrasonographic findings without excessive alcohol consumption,
medications causing hepatic steatosis or other chronic liver diseases. CACS was evaluated using the Agatston method.
Diabetes was defined as cases with fasting serum glucose≥ 126 mg/dl, glycated hemoglobin (HbA1c)≥ 6.5%, or those
taking anti-diabetic medications. Multivariate linear regression analyses were performed with use of the interaction
term of NAFLD × glycemic level and other confounders of CACS such as age, sex, hypertension, body mass index, waist
circumference, HDL cholesterol and triglyceride.
Results: A total of 213 participants with diabetes were included in the study. As 77 subjects (36.2%) had CACS 0,
causing left sided skewness, CACS was analyzed after log transformation to Ln (CACS + 1). A statistically significant
interaction was observed between NAFLD and HbA1c ≥ 7% (P for interaction = 0.014). While NAFLD was not
associated with CACS in the group with HbA1c < 7% (P = 0.229), it was significantly associated in the group with
HbA1c ≥ 7% (P = 0.010) after adjusting for covariates in multivariate analyses.
Conclusions: This study demonstrated an effect modification of glycemic level on the association between NAFLD
and CACS. NAFLD was independently associated with CACS only in diabetes patients with higher HbA1c, after
adjustment for confounders.
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Nonalcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease, with an esti-
mated prevalence of 20-30% in the general population.
In people with obesity or type 2 diabetes, the prevalence
of NAFLD further increases to 70-90% [1,2]. NAFLD is
closely associated with metabolic syndrome, abdominal* Correspondence: yjy@snuh.org
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unless otherwise stated.obesity, and insulin resistance [3]. And NAFLD is also
associated with an increased risk of cardiovascular disease,
independent of the other metabolic syndrome risk factors
[4,5]. Coronary artery calcification is a well-established
surrogate marker of subclinical coronary artery disease,
and is known to reflect the atherosclerotic burden and risk
of cardiovascular disease outcomes [2,6]. Several previous
studies demonstrated the association of coronary artery
calcium score (CACS) with NAFLD, after adjustment for
the other related factors [2,7-11].
Meanwhile, NAFLD is closely associated with diabetes
[3]. There have been conflicting results about thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in patients with diabetes. Some studies indicated that
NAFLD is associated with a higher prevalence of coron-
ary artery disease in type 2 diabetic patients [12,13]. In
contrast, another study showed no significant association
between NAFLD and CACS in patients with diabetes
[14]. In addition, studies evaluating the association of
NAFLD and carotid intima media thickness, another
surrogate marker for cardiovascular disease, have also
reported conflicting results about the association be-
tween carotid intima media thickness and NAFLD in
diabetic patients [14,15].
Therefore, the aim of this study was to evaluate the
association between NAFLD and CACS, specifically in
diabetic patients, after adjustment for other known risk
factors of cardiovascular disease.
Methods
Study population
Patients who visited the Seoul National University Hospital
Gangnam Healthcare Center for health screening between
July 2011 to July 2012 and performed coronary calcium-
scoring computed tomography, hepatic ultrasonography,
and baseline laboratory exams were initially included in the
study. Subjects with other potential causes of chronic liver
disease were excluded as follows: subjects with excessive
alcohol consumption (>30 g/day for men and > 20 g/day
for women), with hepatitis B virus (determined by the
presence of the hepatitis B surface antigen), with the
hepatitis C virus (determined by the presence of the
hepatitis C antibody), or with some other history of
hepatitis, as identified using a detailed medical history
and a questionnaire (primary biliary cirrhosis, Wilson’s
disease, hemochromatosis, and autoimmune hepatitis).
Subjects taking medications that can account for steatosisFigure 1 Flowchart showing details of inclusion and exclusion of the(e.g. tamoxifen, amiodarone, methotrexate) during the
previous year were also excluded. Among them, we se-
lected the patients who were diagnosed with diabetes.
The presence of diabetes was defined as having either a
fasting serum glucose level equal to or greater than
126 mg/dL, glycated hemoglobin (HbA1c) ≥ 6.5% or
consuming medication for diabetes. Participants who
had a history of heart attack, coronary artery disease
including acute myocardial infarction, angina, or congest-
ive heart failure were also excluded. Figure 1 shows flow-
chart of the inclusion and exclusion of the patients.
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by
the Institutional Review Board of Seoul National University
Hospital (H-1406-040-585).Clinical, laboratory and radiological assessments
Each participant completed a questionnaire about past
medical history, and performed an anthropometric assess-
ment, laboratory tests and radiologic tests on the same day.
Height and body weight were measured using a digital scale
while wearing a light gown. The body mass index (BMI)
was calculated as follows: BMI =weight (kg)/height squared
(m2). Waist circumference (WC) was measured with a
tape measure to the nearest millimeter at the midpoint
between the lower costal margin and the iliac crest by a
well-trained examiner. Systolic and diastolic blood pres-
sures were measured twice on the same day in the seated
position, and the mean values were used for analysis. The
presence of hypertension was defined as having systolic
blood pressure over 140 mmHg or diastolic blood pres-
sure over 90 mmHg more than twice or as taking anti-
hypertensive medication. Current smokers were defined
as those who had smoked at least one cigarette per daysubjects.
Kwak et al. Diabetology & Metabolic Syndrome  (2015) 7:28 Page 3 of 6during the previous year. Ex-smokers were defined as tho-
sewho used to smoke cigarettes regularly.
Laboratory examinations included serum aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transpeptidase (GGT), triglyceride, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, uric acid, fasting glucose, HbA1c, hepatitis B
surface antigen, and antibody to hepatitis C virus. Blood
samples were collected from all participants before
10 AM after a 12-h overnight fast. All of the biochemical
determinations were carried out in the same laboratory
using standard laboratory methods.
Diagnosis of fatty liver by ultrasonography
Hepatic ultrasonographic examinations were performed
by experienced radiologists who were blinded to the
clinical and laboratory details of the participants at the
time of the procedure. The diagnosis of fatty liver was
performed by ultrasonography (Acuson, Sequoia 512,
Siemens, Mountain View, CA) using hepatorenal echo
contrast, liver brightness, deep attenuation, and vascular
blurring [16].
Measurement of CACS by multidetector CT
A Scanning of the coronary artery was performed using
a 16-row multi-slice CT scanner (Sensation 16; Siemens
Medical Systems, Erlangen, Germany). CAC scans were
acquired using the standard procedure of the prospective
echocardiography-triggered scan acquisition with a tube
voltage of 120 kV, and 110 effective mAs with a 200 mm
field of view [17]. Data were reconstructed to a 3-mm
slice thickness at a −400 ms acquisition window. The
CACS was then calculated using a CT software program
(Rapidia 2.8; INFINITT, Seoul, Korea) according to the
method described by Agatston et al. [18].
Statistical analysis
The chi-square test was used for categorical variables,
while Student’s t-test and the Mann–Whitney U test
were used for continuous variables to identify the differ-
ences between the subjects with and without NAFLD.
The distribution of CACS was evaluated, and log trans-
formation was considered in the case of left skewness.
We attempted to evaluate if there were any effect modi-
fication by glycemic level in the relationship of NAFLD
and CACS using the interaction term of HbA1c ≥ 7% ×
NAFLD. The HbA1c was divided at the level of 7%, as
current guidelines specify HbA1c targets approximating
or less than 7%, and the mean value of HbA1c level in
this study is nearly 7% [19,20]. Considering collinearity,
several covariates were selected and univariate linear
regression analyses were performed to evaluate the associ-
ation between Ln (CACS + 1) and the covariates. Age, sex,
NAFLD, an interaction term of HbA1c ≥ 7% ×NAFLDand other covariates obtaining a P value < 0.2 in the
univariate analyses were included in the multivariate
linear regression analysis. All statistical analyses were
conducted using SPSS 19 (SPSS Inc., Chicago, IL, USA)
and Stata 13.1 (StataCorp, College Station, Texas, USA).
A two-tailed P value < 0.05 was considered statistically
significant.Results
A total of 213 participants (184 males and 29 females,
mean age 59 years) with diabetes were included in this
study. The mean HbA1c level in the study population
was 6.93% ± 0.89 with a fasting glucose level of 138.5 mg/
dL ± 31.6. Among the diabetic patients, NAFLD was
present in 86 subjects (40.4%). The baseline characteris-
tics of the subjects with and without NAFLD are shown
in Table 1. Seventy-seven subjects (36.2 %) had CACS 0.
The median value of CACS was 11.3 (range, 0–2443.7)
in the control group, and 44.2 (range, 0–1891.7) in the
NAFLD group, showing left sided skewness. Therefore,
we used a log-transformed new dependent variable: Ln
(CACS + 1). We performed univariate linear regression
to elucidate the association of Ln (CACS + 1) for covari-
ates. Considering collinearity, we selected the variable
of HbA1c ≥ 7% among HbA1c, HbA1c ≥ 7% and fasting
glucose level. AST, ALT and GGT were also not evalu-
ated in the regression analyses because of the collinear-
ity to the variable NAFLD. Covariates included age, sex,
hypertension, body mass index, waist circumference,
high-density lipoprotein cholesterol and triglyceride. All
these covariates could be considered as confounders in
the association between NAFLD and CACS.
Ln(CACS + 1) was statistically significantly associated
with increased age (P < 0.001), male sex (P = 0.027), hyper-
tension (P = 0.035), and waist circumference (P = 0.020)
in the univariate linear regression analyses (Table 2).
HbA1c ≥ 7% (P = 0.051) showed marginal significance in
the association with Ln(CACS + 1). In the multivariate
linear regression models with adjustment of covariates
with P < 0.2 from the univariate analyses, the interaction
term HbA1c ≥ 7% × NAFLD was statistically significant.
(P for interaction = 0.014). In addition, there was dose–
response interaction between quartiles of HbA1c level
and NAFLD in the association with CACS (P for inter-
action = 0.002).
Therefore, the multivariate linear regression analysis
was analyzed separately according to the HbA1c level. In
the group with lower HbA1c (HbA1c < 7%), NAFLD was
not significantly associated with Ln (CACS + 1) (P = 0.229).
However, NAFLD was independently associated with
higher Ln (CACS + 1) in the group with higher HbA1c
(HbA1c ≥ 7%), after adjusting for other covariates (P= 0.010)
(Table 3, Figure 2).
Table 1 Baseline characteristics according to groups
Control (n = 127) NAFLD (n = 86) P-value
Age, years old, median (range) 58 (36–80) 58 (38–75) 0.197
Male sex, n (%) 110 (86.6%) 74 (86.0%) 0.906
Hypertension, n (%) 61 (48.0%) 57 (66.3%) 0.009
Smoking, n (%) 0.298
Current or ex-smoker 82 (64.6%) 61 (70.9%)
Unknown 11 (8.7%) 3 (3.5%)
Exercise, n (%) 0.402
Regular exercise 21 (16.5%) 20 (23.3%)
Unknown 35 (27.6%) 19 (22.1%)
Body mass index, kg/m2, median (range) 24.1 (18.5-29.6) 26.2 (19.2-36.5) <0.001
Waist circumference, cm, median (range) 87.5 (69.5-107) 92 (72.5-115) <0.001
Metabolic syndrome, n (%) 45 (36.6%) 59 (68.6%) <0.001
HbA1c, %, median (range) 6.60 (5.8-10.2) 6.8 (5.7-10.6) 0.166
HbA1c≥ 7%, n (%) 45 (35.4%) 37 (43.0%) 0.264
Fasting glucose, mg/dL, median (range) 130 (84–252) 138 (84–307) 0.013
LDL cholesterol, mg/dL, median (range) 117.5 (58–268) 125.5 (51–220) 0.453
HDL cholesterol, mg/dL, median (range) 50 (29–89) 48 (32–67) <0.001
Triglyceride, mg/dL, median (range) 92 (30–529) 135.5 (41–450) <0.001
ALT, IU/L, median (range) 22 (8–64) 33 (11–161) <0.001
AST, IU/L, median (range) 24 (11–112) 26.5 (13–202) 0.062
GGT, IU/L, median (range) 28.0 (8–266) 38.0 (12–243) 0.016
Uric acid, median (range) 5.7 (3–9.6) 5.8 (3.1-8.7) 0.253
CACS, median (range) 11.3 (0–2443.7) 44.2 (0–1891.7) 0.577
Abbreviations: NAFLD Nonalcoholic fatty liver disease, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase.
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Studies investigating the association between nonalco-
holic fatty liver disease (NAFLD) and coronary artery
calcium score (CACS) in diabetic patients have shown
conflicting results. This study showed that NAFLD and
HbA1c level had an interaction with CACS in diabetic pa-
tients. NAFLD was found to be independently associatedTable 2 Univariate linear regression analyses for the
relationship with ln (CACS + 1)
β-coefficient 95% CI P-value
NAFLD 0.628 −0.091-1.347 0.087
Age 0.087 0.046-0.128 <0.001
Male sex 1.158 0.134-2.181 0.027
Hypertension 0.761 0.054-1.468 0.035
Body mass index 0.102 −0.022-0.227 0.107
Waist circumference 0.054 0.009-0.100 0.020
HDL cholesterol −0.027 −0.062-0.009 0.139
Triglyceride 0.005 0.000-0.010 0.075
HbA1c≥ 7% 0.720 −0.004-1.443 0.051
Abbreviations: NAFLD Nonalcoholic fatty liver disease, CI confidence interval.with CACS in diabetic patients with higher HbA1c, but
not in those with lower HbA1c (<7%). This is the first
study demonstrating the effect modification of glycemic
level on the association between NAFLD and CACS,
which suggests that more strict control of hyperglycemia
and more aggressive management of NAFLD could be
implemented to prevent coronary atherosclerosis.
The exact underlying mechanism for the association of
NAFLD and CACS in hyperglycemic conditions is not
yet clear. Multiple highly interrelated factors may con-
tribute to the relationship of NAFLD, CACS and dia-
betes. Some of the possible pathways are as follows [1].
First, NAFLD itself stimulates insulin resistance, leading
to accelerated atherosclerosis [21]. A previous study
demonstrated a linear relationship between hepatic fat
content and hepatic insulin sensitivity [22]. Also, it was
revealed that poor glycemic control in diabetic patients
was associated with insulin resistance, as estimated by
euglycemic hyperinsulinemic clamp [23]. This suggests
that insulin resistance could be amplified in NAFLD pa-
tients with hyperglycemia, which may be associated with
the presence of coronary atherosclerosis. Second, oxida-
tive stress and inflammation is another link of NAFLD,
Table 3 Multivariate linear regression analysis for the
relationship with ln (CACS + 1) according to the HbA1c
level
HbA1c < 7% β-coefficient 95% CI P-value
NAFLD −0.627 −1.654-0.399 0.229
Age 0.091 0.029-0.153 0.004
Male sex 1.252 −0.126-2.629 0.075
Hypertension 0.521 −0.397-1.439 0.263
Body mass index 0.059 −0.283-0.401 0.734
Waist circumference 0.015 −0.108-0.139 0.804
HDL cholesterol −0.014 −0.063-0.035 0.577
Triglyceride 0.006 0.000-0.013 0.059
HbA1c ≥ 7%
NAFLD 1.503 0.373-2.634 0.010
Age 0.123 0.061-0.185 <0.001
Male sex 1.415 −0.203-3.034 0.086
Hypertension 0.364 −0.690-1.418 0.494
Body mass index −0.002 −0.415-0.411 0.991
Waist circumference 0.018 −0.124-0.161 0.800
HDL cholesterol −0.023 −0.084-0.038 0.458
Triglyceride −0.002 −0.012-0.008 0.683
Abbreviations: NAFLD Nonalcoholic fatty liver disease, CI confidence interval.
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ease. Reactive oxygen species produced in hepatic steatosis
induce hepatocyte injury, release cytokines, and makes
pro-inflammatory milieu which progresses the liver dam-
age of NAFLD also adding further atherogenic stimuli
[7,24,25]. Higher HbA1c level has also been found to beFigure 2 Association of nonalcoholic fatty liver disease and coronary
In the group with HbA1c < 7%, NAFLD was not significantly associated with
associated with higher Ln (CACS + 1) in the group with HbA1c≥ 7%, afterassociated with oxidative and pro-inflammatory status,
having specific association with elevated TNF-α and
C-reactive protein, further amplifying the atherogenic
environment [23]. Third, decreased adiponectin concentra-
tions, an adipose-secreted cytokine with anti-atherogenic
properties, is also associated with NAFLD, and independ-
ently predicted cardiovascular disease in large prospective
studies [1,26-28]. Hyperglycemia is also known to be associ-
ated with hypoadiponectinemia [23], therefore additional
decrease of adiponectin caused by NAFLD and hypergly-
cemia may aggravate subclinical atherosclerosis. In addition
to these mechanisms, abnormal lipoprotein metabolism
might also act on the pathways of NAFLD and coronary
artery atherosclerosis in diabetic patients. More studies
are warranted to investigate the exact mechanism of the
interaction between NAFLD and hyperglycemia in the
presence of atherosclerosis.
There were some limitations in this study. First, the
study population is not very large. Second, since this was a
cross-sectional study, it is hard to know the causal rela-
tionship between NAFLD and CACS. A larger-scale pro-
spective study is warranted. Third, ultrasonography was
used to diagnose NAFLD without histologic confirmation
of the liver, which is regarded as the gold standard for
NAFLD diagnosis. However, a histologic diagnosis of
NAFLD in the entire study population is difficult to ac-
complish, and has the risk of complications. Fourth, cau-
tious interpretation is necessary to applying the results to
the general population considering that this study includes
subjects with diabetes who perform coronary CT to evalu-
ate their cardiovascular risk. More male and subjects with
elevated risk of atherosclerosis than general population
might be included in this study.artery calcium score in diabetes patients with higher HbA1c.
Ln (CACS + 1) (P = 0.229). However, NAFLD was independently
adjusting for other covariates (P = 0.010).
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In conclusion, NAFLD was independently associated with
subclinical coronary artery atherosclerosis in diabetic pa-
tients with higher HbA1c (≥7%) after adjustment for other
risk factors, but not in diabetes patients with lower HbA1c
(<7%). More attention should be given to coronary artery
disease in patients with NAFLD, especially those with
hyperglycemia.
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